



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/741,823	12/19/2003	Soumitra S. Ghosh	660088.467	2624

500 7590 10/25/2004

SEED INTELLECTUAL PROPERTY LAW GROUP PLLC  
701 FIFTH AVE  
SUITE 6300  
SEATTLE, WA 98104-7092

EXAMINER

REYES, HECTOR M

ART UNIT PAPER NUMBER

1625

DATE MAILED: 10/25/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

## Office Action Summary

**Application No.**

10/741,823

**Applicant(s)**

GHOSH ET AL.

**Examiner**

Hector M Reyes

**Art Unit**

1625

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) ☒ Responsive to communication(s) filed on 04 August 2004.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) ☒ Claim(s) 1-11 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☐ Claim(s) \_\_\_\_\_ is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☒ Claim(s) 1-11 are subject to restriction and/or election requirement.

**Application Papers**

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

**Priority under 35 U.S.C. § 119**

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
- 1) ☐ Certified copies of the priority documents have been received.
  - 2) ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  - 3) ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

**Attachment(s)**

- |  |   |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892)   | 4) <input type="checkbox"/> Interview Summary (PTO-413)<br>Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)                                   | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)             |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)<br>Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____  |

**Restriction to one of the following inventions is required under 35 U.S.C. 121:**

**ELECTION RESTRICTION REQUEST**

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-9 in part, drawn to **HETEROCYCLIC** compounds, pharmaceutical acceptable salts thereof, stereoisomers thereof and multiple prodrugs thereof, and pharmaceutical compositions comprising the same, classified in multiple classes and multiple subclasses. **This group may be subjected to further restriction. A single disclosed species is hereby requested for search purpose.**
  
- II. Claims 1-9 in part, drawn to **NON HETEROCYCLIC** compounds, pharmaceutical acceptable salts thereof, stereoisomers thereof and multiple prodrugs thereof, and pharmaceutical compositions comprising the same, classified in multiple classes and multiple subclasses. **This group may be subjected to further restriction. A single disclosed species is hereby requested for search purpose.**
  
- III. Claims 10-11 in part, drawn to multiple methods of treating medical conditions or diseases using to pharmaceutical compositions comprising **HETEROCYCLIC** compounds or derivatives thereof classified in multiple classes and multiple subclasses. **This group may be subjected to**

**further restriction. A single disclosed species is hereby requested for search purpose.**

- IV. Claims 10-11 in part, drawn to multiple methods of treating medical conditions or diseases using to pharmaceutical compositions comprising **NON-HETEROCYCLIC** compounds or derivatives thereof classified in multiple classes and multiple subclasses. **This group may be subjected to further restriction. A single disclosed species is hereby requested for search purpose.**
- V. Claims 10-11 in part, drawn to multiple methods of preventing medical conditions or diseases using to pharmaceutical compositions comprising **HETEROCYCLIC** compounds or derivatives thereof classified in multiple classes and multiple subclasses. **This group may be subjected to further restriction. A single disclosed species is hereby requested for search purpose.**
- VI. Claims 10-11 in part, drawn to multiple methods of preventing medical conditions or diseases using to pharmaceutical compositions comprising **NON-HETEROCYCLIC** compounds or derivatives thereof classified in multiple classes and multiple subclasses. **This group may be subjected**

**to further restriction. *A single disclosed species is hereby requested for search purpose.***

The inventions are distinct, each from the other because of the following reasons:

Inventions II and I are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions because each set of compounds embraced by each particular Group does not have the same substantial core. Moreover, each set of compounds embraced by each group has a different structure and reactivity from the others that a reference anticipating one group would not necessarily render the other obvious and to search all the different structurally diverse compounds in a single application would present a serious undue burden to the Examiner.

Inventions I-II AND III-IV are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case it is well known that the prior art teaches alternatives treatments for the diseases embraced in the instant claims. For instance there are multiple methods for treating certain particular cancers, which do not require at all the compounds described in the instant application. On the other hand, the

Art Unit: 1625

said products can be use in synthetic procedure to prepare more complex organic targets.

Groups III and IV as well as Groups V and VI are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions because compounds required in the methods of treatment as described in Group III are not required for the methods of treatment of Group IV, therefore each invention is capable of use independently from the other. Similarly, compounds required in the methods of prevention as described in Group V are not required for the methods of treatment of Group VI, therefore each invention is capable of use independently from the other.

Groups III-IV and V-IV are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions because methods of treatment as described in Group III –IV are different from the methods of prevention described in Groups V and VI, since the required steps describing the enablement for each kind of method as well as the final result obtained in each invention is different for each invention. For instance, once the prevention of a given disease ore medical condition is achieved, there is no need for the treatment of the said particular disease or medical condition.

Art Unit: 1625

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, restriction for examination purposes as indicated is proper.

Because these inventions are distinct for the reasons given above and the search required for a given Group is not required for any other Group, restriction for examination purposes as indicated is proper.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete **must include an election of the invention to be examined even though the requirement be traversed** (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

**In the event that Applicant's election is directed to a group drawn to compounds salts and compositions thereof, and if the said compounds, salts and compositions are found allowable, the Examiner is kindly willing to rejoin one method of using the said particular compounds limited to the scope of the**

Art Unit: 1625

**allowable compounds and provided that claims describing the said methods of using are free from any 35 USC 112 issues.**

**CONCLUSION**

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Hector M Reyes whose telephone number is (571) 272-0691. The examiner can normally be reached on M-F (9:00 AM-5:30 PM).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's mentor, Rita Desai can be reached on (571) 272-0684. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Hector M. Reyes PhD JD  
Reg # P-54, 846  
Au 1625  
October 21, 2004

*RDesai*  
10/21/04



Application/Control Number: 10/741,823

Art Unit: 1625

Page 8